Additional trials are ongoing for the CXCR4 antagonist BL-040 in NSCLC (NCT03337698), in AML in combination with atezolizumab (NCT03154827), in metastatic pancreatic cancer (NCT02907099), and in aplastic anemias or hypoplastic myelodysplastic Syndrome (NCT02462252) and several others. The gene discussed is CXCR4; the disease is non-small cell lung carcinoma.